| CUREVAC N.V. O.N. |
| Date/Time | / |
| Chg. / Chg.(%) | - / |
| Bid | - |
| Ask | - |
| Open | - |
| Previous Close | - |
| High | - |
| Low | - |
| Volume [EUR] | - |
| Volume [Units] | |
| Price fixings | |
| ISIN | NL0015436031 |
| Security | 5CV |
| Exchange | Frankfurt |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| NASDAQ | 6.6200 |  |
516,672 |
| TradeGate | 6.12 | |
118,446 |
| Xetra | 6.144 | |
38,400 |
| Cboe US | 6.61 | |
14,132 |
| IEX | 6.61 | |
12,864 |
| Frankfurt | 6.1000 | |
12,685 |
| gettex | 6.103 | |
9,733 |
| Stuttgart | 6.099 | |
8,622 |
| München | 6.249 | |
250 |
| Quotrix | 6.1010 | |
230 |
| Düsseldorf | 6.081 | |
0 |
| Hamburg | 6.362 |  |
0 |
| Berlin | 6.350 | |
0 |
| Hannover | 6.362 | |
0 |
| Vienna Globa.. | 6.12 | |
0 |
| Lang & Schwa.. | 6.050 | |
|
| London Inter.. | 7.160 | 11,325 | |
| Bulgaria | 10.26 | |
0 |
News
- CureVac sues BioNTech over vaccine technology
07/05/2022 / 13:57 - TeleTrader - US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant
03/25/2022 / 21:04 - GlobeNewswire - GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19
01/13/2022 / 15:02 - GlobeNewswire - GSK and Vir Biotechnology Announce United States Government Agreement to Purchase Additional Supply of Sotrovimab, Authorized for the Early Treatment of COVID-19
01/11/2022 / 13:12 - GlobeNewswire - Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19
12/17/2021 / 14:16 - GlobeNewswire
Personal area
Real-timeClick on 
to activate push quotes.
to activate push quotes.